Full metadata record
DC FieldValueLanguage
dc.creatorRodriguez, J. (José)-
dc.creatorConde, E. (Eulogio)-
dc.creatorGutierrez, A. (Antonio)-
dc.creatorArranz, R. (R.)-
dc.creatorGandarillas, M. (M.)-
dc.creatorLeon, A. (Angel)-
dc.creatorOjanguren, J. (Jesús)-
dc.creatorSureda, A. (Anna)-
dc.creatorCarrera, D. (D,)-
dc.creatorBendandi, M. (Maurizio)-
dc.creatorMoraleda, J. (José)-
dc.creatorRibera, J.M. (José María)-
dc.creatorAlbo, C. (Carmen)-
dc.creatorMorales, A. (Alfonso)-
dc.creatorGarcia, J. (Juan Carlos)-
dc.creatorFernandez, P. (Pascual)-
dc.creatorCañigral, G. (G.)-
dc.creatorBergua, J. (J.)-
dc.creatorCaballero, M.D. (M.D.)-
dc.creatorGrupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO)-
dc.date.accessioned2011-11-30T09:58:19Z-
dc.date.available2011-11-30T09:58:19Z-
dc.date.issued2007-
dc.identifier.citationRodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007 Apr;78(4):290-296.es_ES
dc.identifier.issn1600-0609-
dc.identifier.urihttp://hdl.handle.net/10171/20016-
dc.description.abstractAbstract OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%). RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL. CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.es_ES
dc.language.isoenges_ES
dc.publisherJohn Wiley and Sonses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAngioimmunoblastic T-cell lymphomaes_ES
dc.subjectAutologous transplantationes_ES
dc.titleProlonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experiencees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://bit.ly/u0j2sEes_ES

Files in This Item:
File: 
Eur J Haem 2007_78.pdf
Description: 
Size: 
535,64 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.